Physician profile
Stacy Meeks
NPI 1497104061
$4,293.38
in general payments reported to CMS, 2019-2025
29 companies · $35.34 in 2025
The $35.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $818 · 2021: $907 · 2022: $1,028 · 2023: $1,125 · 2024: $126 · 2025: $35.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.28 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $847.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $689.84 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $508.11 | 2019-2023 | Belsomra, Steglatro, Segluromet |
| Astrazeneca Pharmaceuticals LP | $397.54 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.90 | 2019-2024 | Jardiance, Synjardy |
| Amgen INC. | $263.59 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $242.05 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $145.36 | 2021-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $135.84 | 2019-2023 | Ajovy |
| Amarin Pharma, INC. | $129.33 | 2019-2022 | |
| Pfizer INC. | $74.75 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $57.47 | 2021-2023 | Eliquis |
| Allergan, INC. | $47.18 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.26 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $45.00 | 2022-2023 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $42.13 | 2022-2024 | Freestyle Libre 3 |
| Organon LLC | $40.98 | 2021-2023 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.41 | 2023 | |
| Mylan Specialty L.P. | $34.68 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.58 | 2021 | |
| Glaxosmithkline, LLC. | $27.89 | 2022-2023 | Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $19.06 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.96 | 2019 | |
| Sanofi Pasteur INC. | $13.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.15 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.